Company news
Remegen Co. Ltd. Class A (SSE:688331) news
Remegen Co. Ltd. Class A news releases on 6ix. Latest, Jun 17, 2025: RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia…
Press releases — page 2
RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis
June 17, 2025
Indicative Announcement on Obtaining Term Compensation for Core Drug Patent
June 13, 2025
2025 ASCO ｜Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer
June 2, 2025
Announcement on Completing the Issuance of H Shares
May 29, 2025
RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China
May 27, 2025
Notice on Convening the 2024 Annual General Meeting, the 1st A-share General Meeting of 2025, and the 1st H-Share General Meeting of 2025
May 26, 2025
Announcement on Reply to Letter of Regulatory Inquiry from Shanghai Stock Exchange
May 23, 2025
Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Shandong Jurisdiction
May 13, 2025
Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS
May 12, 2025
Announcement on the First Vesting Results and Share Listing in the First Vesting Period of the Second Class A Interest and the First Class B Interest Initially Granted under the 2022 A-share Restricted Stock Incentive Plan
April 30, 2025
Report for Q1 2025
April 28, 2025
Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing
April 25, 2025
Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis
April 8, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
April 2, 2025
Announcement on 2024 Annual Profit Distribution Plan
March 27, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
March 14, 2025
Announcement on Resolutions of the 19th Meeting of the 2nd Board of Directors
February 27, 2025
Announcement on Resignation of Director and Core Technical Personnel
February 6, 2025
Annual Earnings Preannouncement for 2024
January 16, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
January 10, 2025
Announcement on the Completion of Implementing Share Increase Plan by Actual Controllers' Controlled Companies and Results of Share Increase
January 8, 2025
Announcement on Eligibility for the Second Vesting Period of Class A Rights in 2022 A-share Restricted Share Incentive Plan
December 30, 2024